Metastasis from Malignant Tumor of Cervix clinical trials at UCSF
1 research study open to eligible people
When cervical cancer spreads to other areas, it is called metastasis. UCSF is conducting a study on a treatment called NBTXR3, used alongside radiotherapy for advanced cancers. This research includes testing the effects when combined with anti-PD-1 therapy.
Showing trials for
NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy
open to eligible people ages 18 years and up
The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.
San Francisco, California and other locations
Our lead scientists for Metastasis from Malignant Tumor of Cervix research studies include Jason Chan.
Last updated: